France-based MedinCell (Paris:MEDCL) has signed a contract with the Bill & Melinda Gates Foundation for up to an additional USD19m to be granted over four years, it was reported on Friday.
The grant is intended to fund preclinical activities and a phase one clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). In accordance with the Global Access strategy of both partners and to ensure a significant impact on women's lives, the objective is to make the product widely available.
The grant is structured in advanced instalments to include the costs that will be incurred by the project. Depending on the options chosen and on the advancement of the program, up to USD11.75m is to be raised over the next 12 months including a first tranche of USD4.75m to be paid immediately. The additional USD7.25m is likely to be collected later.
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering